SEC Comment Letter for Opus Genetics, Inc. (IRD) (CIK 0001228627) (IRD) — Jun 2, 2017
Opus Genetics, Inc. (IRD) (CIK 0001228627)
Date: June 2, 2017 · CIK: 0001228627 · Accession: 0000000000-17-019353
AI Filing Summary & Sentiment
Reasoning
Letter
June 2, 2017 Peter Suzdak Chief Executive Officer Rexahn Pharmaceuticals, Inc. 15245 Shady Grove Road, Suite 455 Rockville, MD 20850 Rexahn Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed May 26, 2017 File No. 333-218285Re: Dear Mr. Suzdak: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dorrie Yale at 202-551-8776 with any questions. Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
June 2, 2017
Peter Suzdak
Chief Executive Officer
Rexahn Pharmaceuticals, Inc.
15245 Shady Grove Road, Suite 455
Rockville, MD 20850
Rexahn Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed May 26, 2017
File No. 333-218285Re:
Dear Mr. Suzdak:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dorrie Yale at 202-551-8776 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance